small molecule glp 1 agonist In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule GLP-1 receptor orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with Peptidyl and Non-Peptidyl Oral Glucagon-Like

Exenatide, the first GLP-1RA approved in 2005, demonstrated clinical efficacy but its low homology with human GLP-1 and gastrointestinal side effects restricted widespread use (Muttenthaler et al., 2021)

Semaglutide, which is the most potent pure GLP-1 RA available, has produced weight loss of up to 17% to 20% in clinical trials designed to assess its effect on weight, says Dr

Well also clear up a few common misconceptions that can cause confusion

D.MichaelidesM.BalerR

Drowsiness after injection is normal and expected

Access and affordability constraints limit the population that can benefit from current therapies